On June 21, 2025, Perspective Therapeutics, Inc. announced reaching alignment with the U.S. FDA to open a new dosing cohort in their clinical trial for treating specific neuroendocrine tumors and presented data at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting.